Cargando…

Synchrotron Fourier Transform Infrared Microscopy Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis Cancer Cells

[Image: see text] Janus kinase (JAK) deregulation of the JAK/signal transducers and activators of transcription pathway leads to myelofibrosis that can be treated by JAK inhibitors including Ruxolitinib and Tofacitinib. Even though both inhibitors are effective against myelofibrosis, each of them ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Siriwaseree, Jeeraprapa, Sanachai, Kamonpan, Aiebchun, Thitinan, Tabtimmai, Lueacha, Kuaprasert, Buabarn, Choowongkomon, Kiattawee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260937/
https://www.ncbi.nlm.nih.gov/pubmed/35811912
http://dx.doi.org/10.1021/acsomega.2c02404
_version_ 1784742154121248768
author Siriwaseree, Jeeraprapa
Sanachai, Kamonpan
Aiebchun, Thitinan
Tabtimmai, Lueacha
Kuaprasert, Buabarn
Choowongkomon, Kiattawee
author_facet Siriwaseree, Jeeraprapa
Sanachai, Kamonpan
Aiebchun, Thitinan
Tabtimmai, Lueacha
Kuaprasert, Buabarn
Choowongkomon, Kiattawee
author_sort Siriwaseree, Jeeraprapa
collection PubMed
description [Image: see text] Janus kinase (JAK) deregulation of the JAK/signal transducers and activators of transcription pathway leads to myelofibrosis that can be treated by JAK inhibitors including Ruxolitinib and Tofacitinib. Even though both inhibitors are effective against myelofibrosis, each of them has a different mode of action in the cells. Ruxolitinib is an inhibitor for selective JAK1/2, and Tofacitinib is an inhibitor for JAK3. This study evaluated the chemical fingerprints of TF-1 cells after JAK inhibitor treatments by the synchrotron Fourier transform infrared microspectroscopy (S-FTIR) spectrum. Tofacitinib and Ruxolitinib treatments in TF-1 cells were applied with a chemical fingerprint approach in S-FTIR spectroscopy and in vitro cytotoxicity in a cell-based assay. Principal component analysis or PCA was utilized to classify three cell treatments with three biochemical alteration absorbances of lipid vibration by the C–H stretching, protein amide I that appeared from the C=O stretching, and a P=O phosphodiester bond from nucleic acids. The results showed that the inhibition effect of Ruxolitinib on the TF-1 cell lines was two-fold higher than Tofacitinib. PCA distinguishes untreated and drug-treated cells by detecting cellular biochemical alteration. The loading plots identify that proteins and nucleic acids were the different main components in disparate cell treatments. Tofacitinib was distinct from the others in lipid and nucleic acid. The second derivative spectra of the three molecular components had decreased lipid production and accumulation, changes in secondary structures in proteins, and a high level of RNA overexpression in cell treatment. The JAK inhibitors caused different spectroscopic biomarkers of the modifications of secondary protein conformation, stimulated cell lipid accumulation, and phosphorylation from untreated cells. The alteration of cellular biochemical components suggests that FTIR is a potential tool to analyze specific patterns of drug cellular responses at the molecular level.
format Online
Article
Text
id pubmed-9260937
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-92609372022-07-08 Synchrotron Fourier Transform Infrared Microscopy Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis Cancer Cells Siriwaseree, Jeeraprapa Sanachai, Kamonpan Aiebchun, Thitinan Tabtimmai, Lueacha Kuaprasert, Buabarn Choowongkomon, Kiattawee ACS Omega [Image: see text] Janus kinase (JAK) deregulation of the JAK/signal transducers and activators of transcription pathway leads to myelofibrosis that can be treated by JAK inhibitors including Ruxolitinib and Tofacitinib. Even though both inhibitors are effective against myelofibrosis, each of them has a different mode of action in the cells. Ruxolitinib is an inhibitor for selective JAK1/2, and Tofacitinib is an inhibitor for JAK3. This study evaluated the chemical fingerprints of TF-1 cells after JAK inhibitor treatments by the synchrotron Fourier transform infrared microspectroscopy (S-FTIR) spectrum. Tofacitinib and Ruxolitinib treatments in TF-1 cells were applied with a chemical fingerprint approach in S-FTIR spectroscopy and in vitro cytotoxicity in a cell-based assay. Principal component analysis or PCA was utilized to classify three cell treatments with three biochemical alteration absorbances of lipid vibration by the C–H stretching, protein amide I that appeared from the C=O stretching, and a P=O phosphodiester bond from nucleic acids. The results showed that the inhibition effect of Ruxolitinib on the TF-1 cell lines was two-fold higher than Tofacitinib. PCA distinguishes untreated and drug-treated cells by detecting cellular biochemical alteration. The loading plots identify that proteins and nucleic acids were the different main components in disparate cell treatments. Tofacitinib was distinct from the others in lipid and nucleic acid. The second derivative spectra of the three molecular components had decreased lipid production and accumulation, changes in secondary structures in proteins, and a high level of RNA overexpression in cell treatment. The JAK inhibitors caused different spectroscopic biomarkers of the modifications of secondary protein conformation, stimulated cell lipid accumulation, and phosphorylation from untreated cells. The alteration of cellular biochemical components suggests that FTIR is a potential tool to analyze specific patterns of drug cellular responses at the molecular level. American Chemical Society 2022-06-23 /pmc/articles/PMC9260937/ /pubmed/35811912 http://dx.doi.org/10.1021/acsomega.2c02404 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Siriwaseree, Jeeraprapa
Sanachai, Kamonpan
Aiebchun, Thitinan
Tabtimmai, Lueacha
Kuaprasert, Buabarn
Choowongkomon, Kiattawee
Synchrotron Fourier Transform Infrared Microscopy Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis Cancer Cells
title Synchrotron Fourier Transform Infrared Microscopy Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis Cancer Cells
title_full Synchrotron Fourier Transform Infrared Microscopy Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis Cancer Cells
title_fullStr Synchrotron Fourier Transform Infrared Microscopy Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis Cancer Cells
title_full_unstemmed Synchrotron Fourier Transform Infrared Microscopy Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis Cancer Cells
title_short Synchrotron Fourier Transform Infrared Microscopy Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis Cancer Cells
title_sort synchrotron fourier transform infrared microscopy spectra in cellular effects of janus kinase inhibitors on myelofibrosis cancer cells
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260937/
https://www.ncbi.nlm.nih.gov/pubmed/35811912
http://dx.doi.org/10.1021/acsomega.2c02404
work_keys_str_mv AT siriwasereejeeraprapa synchrotronfouriertransforminfraredmicroscopyspectraincellulareffectsofjanuskinaseinhibitorsonmyelofibrosiscancercells
AT sanachaikamonpan synchrotronfouriertransforminfraredmicroscopyspectraincellulareffectsofjanuskinaseinhibitorsonmyelofibrosiscancercells
AT aiebchunthitinan synchrotronfouriertransforminfraredmicroscopyspectraincellulareffectsofjanuskinaseinhibitorsonmyelofibrosiscancercells
AT tabtimmailueacha synchrotronfouriertransforminfraredmicroscopyspectraincellulareffectsofjanuskinaseinhibitorsonmyelofibrosiscancercells
AT kuaprasertbuabarn synchrotronfouriertransforminfraredmicroscopyspectraincellulareffectsofjanuskinaseinhibitorsonmyelofibrosiscancercells
AT choowongkomonkiattawee synchrotronfouriertransforminfraredmicroscopyspectraincellulareffectsofjanuskinaseinhibitorsonmyelofibrosiscancercells